Novartis AG NVS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.20B | 3.26B | 3.16B | 2.41B | 3.93B |
| Total Depreciation and Amortization | 1.31B | 1.20B | 1.19B | 1.18B | 1.26B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.33B | 1.44B | 385.00M | 962.00M | 320.00M |
| Change in Net Operating Assets | -338.00M | -19.00M | -1.05B | -2.28B | 1.06B |
| Cash from Operations | 5.50B | 5.88B | 3.68B | 2.26B | 6.57B |
| Capital Expenditure | -392.00M | -321.00M | -346.00M | -609.00M | -354.00M |
| Sale of Property, Plant, and Equipment | -- | 26.00M | 5.00M | 1.00M | 1.00M |
| Cash Acquisitions | -1.11B | -2.74B | -12.04B | -1.16B | -93.00M |
| Divestitures | 42.00M | 62.00M | -2.00M | -9.00M | -64.00M |
| Other Investing Activities | -287.00M | -129.00M | 648.00M | -328.00M | -350.00M |
| Cash from Investing | -1.75B | -3.11B | -11.74B | -2.10B | -860.00M |
| Total Debt Issued | -- | 2.19B | 11.67B | 5.13B | 135.00M |
| Total Debt Repaid | -768.00M | -87.00M | -92.00M | -1.84B | -646.00M |
| Issuance of Common Stock | -- | 14.00M | -- | 4.00M | 2.00M |
| Repurchase of Common Stock | -1.70B | -1.20B | -1.88B | -1.48B | -2.30B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -2.87B | -6.20B | 0.00 | -- |
| Other Financing Activities | 2.00M | -67.00M | 78.00M | -124.00M | 22.00M |
| Cash from Financing | -2.46B | -2.02B | 3.58B | 1.68B | -2.79B |
| Foreign Exchange rate Adjustments | -39.00M | -18.00M | -77.00M | 36.00M | -22.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.25B | 739.00M | -4.56B | 1.88B | 2.90B |